

Harnessing the Growth Potential of the Healthcare Industry

With Global Healthcare spending exceeding **\$8 trillion*** in 2018 and projected to increase at an annual rate of **5.4% through 2022***, the AlphaCentric LifeSci Healthcare Fund Leverages the experience of 20+ PhDs and MDs combined with the hands-on scientific achievements of Portfolio Manager, Mark Charest to invest in Biotech and Healthcare equities and capture long term capital appreciation through fundamental, thesis-driven investments.



Mark G. Charest, Ph.D.
Portfolio Manager

Mark is an inventor on 8 drug patents and has a successful 10+ year career as a healthcare investor at several specialized \$1B+ AUM healthcare fund managers.

- Ph.D. and M.S. in Chemistry and Chemical Biology from Harvard University, National Science Foundation Graduate Research Fellow.
- Led Medicinal Chemistry Lab at the Novartis Institutes for BioMedical Research focused on Oncology drug discovery
- Was a Kauffman Fellow at Panorama Capital where he served on the board of directors of Itero Biopharmaceuticals. He was also a board observer at Presidio Pharmaceuticals and PowerVision.
- Portfolio Manager at New Leaf Venture Partners and Associate at Great Point Partners
- SVP at Tekla Capital Management

The advisor has contractually agreed to waive fees and/or reimburse expenses to maintain the Fund's total annual operating ratio at 1.65%, 2.40%, and 1.40% for Class A shares, Class C shares and Class I shares, respectively, through July 31, 2021..

*Source: Deloitte 2019 Healthcare Outlook

Fund Summary			
Advisor	AlphaCentric Advisors, LLC		
Sub-Advisor	LifeSci Fund Management		
Fund Objective	The Fund's investment objective is long-term capital appreciation.		
Strategy	<ul style="list-style-type: none"> • Designed to outperform broad market exposure by investing in Life Sciences and Healthcare equities leveraging proprietary primary research • Science-driven biotechnology and pharmaceutical companies addressing high unmet medical needs are emphasized 		
Sectors	The Fund concentrates its investments (25%+) in the biotech and pharmaceutical; health care facilities and services; and medical equipment and devices industries, collectively		
Flexible Market Cap	Core: Compelling profitable large caps Opportunistic: Highly innovative SMID caps with high growth potential		
Region	US focused with ability to invest in EU+		
Benchmark	Broad S&P 500 (primary) Sector S&P Biotech Index		
Minimum Investment	\$2,500 (\$1,000 for Retirement Plans)		
Expense Ratio	A Share	C Share	I Share
Net Expense	1.73%	2.40%	1.48%
Gross Expense	2.61%	3.36%	2.36%

Alpha Centric Life Sci Healthcare Fund Driven by Proprietary Primary Research



LifeSci Partners is the leading provider of strategic scientific consulting services in the areas of investor relations, public relations, corporate communications, executive search and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and corporate communications, LifeSci Partners delivers unparalleled services to life sciences companies globally.

With global presences in New York, Chicago, Boston, London, Geneva, Paris, Asia and Tel-Aviv, LifeSci Advisors leverages its relationships and local knowledge in multiple territories around the world to provide high value services for clients.



LifeSci
Advisors

LifeSci
Public Relations

LifeSci
Capital

LifeSci
Venture

LifeSci
Search

LifeSci
Partnering & Analytics

The maximum sales charge for Class "A" Shares is 5.75%. Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. To obtain the most recent month end performance information or the funds prospectus please call the fund, toll free at 1-844-ACFUNDS (844-223-8637). You can also obtain a prospectus at www.AlphaCentricFunds.com.

The Fund is a new mutual fund and has a limited history of operations for investors to evaluate. The fund may be non-diversified and the value and/or volatility of a single issuer could have a greater impact on fund performance. The Fund may be susceptible to an increased risk of loss due to adverse occurrences affecting the Fund more than the market as a whole, because the Funds investments are concentrated. Some securities held by the Fund may be difficult to sell, or illiquid, particularly during times of market turmoil. The Funds' can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The funds' can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including, but not limited to, products becoming obsolete, and entrance of competing products. Further, these companies are dependent on patent protection, and the expiration of patents may adversely affect the profitability of the companies. The Fund invests in IPOs at the time of the initial public offering and in post-IPO trading. IPOs are often subject to extreme price volatility and speculative trading. The ETFs in which the fund invests are subject to advisory fees and other expenses and as a result the cost of investing in the fund will be higher than the cost of investing directly in the underlying funds. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. All investments involve risks, including possible loss of principal, there is no assurance that the Fund will achieve its investment objective